- Home
- KALV vs LXRX Comparison
KALV vs LXRX Comparison
Compare KALV & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- LXRX
- Stock Information
- Founded
- KALV N/A
- LXRX 1995
- Country
- KALV United States
- LXRX United States
- Employees
- KALV N/A
- LXRX N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- KALV Health Care
- LXRX Health Care
- Exchange
- KALV Nasdaq
- LXRX Nasdaq
- Market Cap
- KALV 523.1M
- LXRX 690.5M
- IPO Year
- KALV N/A
- LXRX 2000
- Fundamental
- Price
- KALV $12.09
- LXRX $2.01
- Analyst Decision
- KALV Strong Buy
- LXRX Buy
- Analyst Count
- KALV 4
- LXRX 2
- Target Price
- KALV $29.00
- LXRX $10.00
- AVG Volume (30 Days)
- KALV 489.8K
- LXRX 2.5M
- Earning Date
- KALV 12-05-2024
- LXRX 11-06-2024
- Dividend Yield
- KALV N/A
- LXRX N/A
- EPS Growth
- KALV N/A
- LXRX N/A
- EPS
- KALV N/A
- LXRX N/A
- Revenue
- KALV N/A
- LXRX $3,641,000.00
- Revenue This Year
- KALV N/A
- LXRX $1,288.95
- Revenue Next Year
- KALV $250.03
- LXRX $276.56
- P/E Ratio
- KALV N/A
- LXRX N/A
- Revenue Growth
- KALV N/A
- LXRX 794.59
- 52 Week Low
- KALV $7.21
- LXRX $0.92
- 52 Week High
- KALV $16.88
- LXRX $3.73
- Technical
- Relative Strength Index (RSI)
- KALV 55.89
- LXRX 73.60
- Support Level
- KALV $10.84
- LXRX $1.60
- Resistance Level
- KALV $12.50
- LXRX $1.84
- Average True Range (ATR)
- KALV 0.53
- LXRX 0.10
- MACD
- KALV 0.17
- LXRX 0.04
- Stochastic Oscillator
- KALV 72.97
- LXRX 81.97
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.